Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 87057 | 2.32 |
09:34 ET | 15569 | 2.335 |
09:36 ET | 46470 | 2.315 |
09:38 ET | 22470 | 2.37 |
09:39 ET | 5335 | 2.325 |
09:41 ET | 35139 | 2.355 |
09:43 ET | 6812 | 2.355 |
09:45 ET | 10967 | 2.3207 |
09:48 ET | 39318 | 2.325 |
09:50 ET | 32793 | 2.355 |
09:52 ET | 3203 | 2.345 |
09:54 ET | 4572 | 2.345 |
09:56 ET | 24275 | 2.345 |
09:57 ET | 4440 | 2.355 |
09:59 ET | 68654 | 2.405 |
10:01 ET | 47278 | 2.435 |
10:03 ET | 47942 | 2.3799 |
10:06 ET | 12415 | 2.385 |
10:08 ET | 2573 | 2.385 |
10:10 ET | 14388 | 2.41 |
10:12 ET | 60644 | 2.45 |
10:14 ET | 77078 | 2.448 |
10:15 ET | 25213 | 2.43 |
10:17 ET | 31888 | 2.425 |
10:19 ET | 17109 | 2.46 |
10:21 ET | 36836 | 2.49 |
10:24 ET | 268317 | 2.57 |
10:26 ET | 78948 | 2.575 |
10:28 ET | 73835 | 2.5905 |
10:30 ET | 29141 | 2.5991 |
10:32 ET | 36332 | 2.595 |
10:33 ET | 27852 | 2.595 |
10:35 ET | 63861 | 2.625 |
10:37 ET | 68248 | 2.655 |
10:39 ET | 135444 | 2.69 |
10:42 ET | 68481 | 2.715 |
10:44 ET | 71412 | 2.745 |
10:46 ET | 72711 | 2.715 |
10:48 ET | 40923 | 2.7701 |
10:50 ET | 124838 | 2.7701 |
10:51 ET | 32122 | 2.775 |
10:53 ET | 19738 | 2.78 |
10:55 ET | 72309 | 2.81 |
10:57 ET | 37469 | 2.81 |
11:00 ET | 162988 | 2.855 |
11:02 ET | 57073 | 2.859 |
11:04 ET | 184788 | 2.805 |
11:06 ET | 141063 | 2.77 |
11:08 ET | 72244 | 2.765 |
11:09 ET | 62466 | 2.74 |
11:11 ET | 32813 | 2.72 |
11:13 ET | 27980 | 2.72 |
11:15 ET | 12833 | 2.74 |
11:18 ET | 53542 | 2.83 |
11:20 ET | 63398 | 2.76 |
11:22 ET | 43099 | 2.82 |
11:24 ET | 50372 | 2.8 |
11:26 ET | 30299 | 2.8201 |
11:27 ET | 51571 | 2.83 |
11:29 ET | 14378 | 2.78 |
11:31 ET | 9486 | 2.79 |
11:33 ET | 36400 | 2.83 |
11:36 ET | 40745 | 2.78 |
11:38 ET | 16936 | 2.79 |
11:40 ET | 22993 | 2.805 |
11:42 ET | 77212 | 2.76 |
11:44 ET | 18784 | 2.75 |
11:45 ET | 18157 | 2.75 |
11:47 ET | 25233 | 2.745 |
11:49 ET | 19904 | 2.705 |
11:51 ET | 15645 | 2.705 |
11:54 ET | 8852 | 2.7088 |
11:56 ET | 6332 | 2.71 |
11:58 ET | 3609 | 2.7092 |
12:00 ET | 35051 | 2.735 |
12:02 ET | 21758 | 2.75 |
12:03 ET | 17422 | 2.775 |
12:05 ET | 14100 | 2.7749 |
12:07 ET | 13718 | 2.765 |
12:09 ET | 9762 | 2.7799 |
12:12 ET | 16825 | 2.775 |
12:14 ET | 11359 | 2.745 |
12:16 ET | 19675 | 2.795 |
12:18 ET | 3347 | 2.785 |
12:20 ET | 103550 | 2.825 |
12:21 ET | 329431 | 2.85 |
12:23 ET | 20458 | 2.855 |
12:25 ET | 8597 | 2.85 |
12:27 ET | 29357 | 2.89 |
12:30 ET | 11625 | 2.9244 |
12:32 ET | 27133 | 2.895 |
12:34 ET | 12330 | 2.895 |
12:36 ET | 25874 | 2.915 |
12:38 ET | 6792 | 2.915 |
12:39 ET | 10868 | 2.8999 |
12:41 ET | 5687 | 2.9 |
12:43 ET | 13084 | 2.92 |
12:45 ET | 9432 | 2.9 |
12:48 ET | 16993 | 2.925 |
12:50 ET | 6277 | 2.915 |
12:52 ET | 9000 | 2.925 |
12:54 ET | 10287 | 2.915 |
12:56 ET | 19685 | 2.9301 |
12:57 ET | 40256 | 2.93 |
12:59 ET | 5748 | 2.93 |
01:01 ET | 97370 | 2.915 |
01:03 ET | 10155 | 2.92 |
01:06 ET | 14638 | 2.91 |
01:08 ET | 11241 | 2.925 |
01:10 ET | 4241 | 2.925 |
01:12 ET | 26623 | 2.9301 |
01:14 ET | 8066 | 2.9208 |
01:15 ET | 42545 | 2.9098 |
01:17 ET | 3066 | 2.905 |
01:19 ET | 2467 | 2.905 |
01:21 ET | 13362 | 2.915 |
01:24 ET | 35466 | 2.895 |
01:26 ET | 5626 | 2.8901 |
01:28 ET | 1868 | 2.895 |
01:30 ET | 2427 | 2.895 |
01:32 ET | 2770 | 2.8908 |
01:33 ET | 3685 | 2.895 |
01:35 ET | 2832 | 2.8975 |
01:37 ET | 2495 | 2.895 |
01:39 ET | 3132 | 2.895 |
01:42 ET | 31296 | 2.895 |
01:44 ET | 24621 | 2.905 |
01:46 ET | 5794 | 2.915 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 1.7B | -17.6x | --- |
Syndax Pharmaceuticals Inc | 1.7B | -6.2x | --- |
Kura Oncology Inc | 1.6B | -9.5x | --- |
Sana Biotechnology Inc | 1.7B | -5.0x | --- |
Structure Therapeutics Inc | 1.7B | -15.6x | --- |
Edgewise Therapeutics Inc | 1.6B | -11.0x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.7B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.39 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -17.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.